ArticleBritish journal of cancer2025
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities.British journal of cancer · 2026Article
- Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study.The oncologist · 2026Observational
- Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.Future oncology (London, England) · 2026Review
- Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design.Current oncology (Toronto, Ont.) · 2026Review
- Real-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC.Cancers · 2026Article
- Advances in the management of neuroendocrine tumours: Evidence from a systematic review.Biomedical reports · 2026Article
- Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study.Cancers · 2026Article
- Recapitulating lung cancer metastasisOncology reports · 2026Review
- Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.NPJ precision oncology · 2026Article
- Article
- Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.Health science reports · 2026Article
- Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study.Frontiers in medicine · 2026Article
- Checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: a cohort study with transcriptomic analysis of inflammatory mechanisms.BMC pulmonary medicine · 2025Article
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway.BJC reports · 2025Article
- Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.Translational lung cancer research · 2025Article
- First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.Immunotherapy · 2025Article
- Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.Journal for immunotherapy of cancer · 2025Article
- Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia.Biomedicines · 2025Article
- Diagnosis and treatment of lung cancer: A molecular perspective.World journal of clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBased on favourable results from clinical trials, immune checkpoint inhibitors (ICI) have become the standard first line (1 L) systemic anticancer treatment (SACT) for advanced stage non-small cell lung cancer (NSCLC) without targetable mutations. We evaluate whether these results are generalizable to everyday clinical practice and compare overall survival (OS) of patients treated with ICI to a historical cohort of patients treated with chemotherapy and results from clinical trials.
methodsOur study comprised all advanced NSCLC patients initiating SACT in 2012-21 in Norway. Clinical characteristics and treatment information was retrieved from Norwegian Health Registries.
resultsSurvival for all 8416 advanced NSCLC patients treated with SACT increased concurrently with the gradual implementation of ICIs. Median OS of patients treated with 1 L pembrolizumab after 2017 was better (mono-/combination therapy: 13.8/12.8 months) than for patients treated with chemotherapy before 2017 (8.0 months). Although median OS for patients treated with pembrolizumab was lower in clinical practice than clinical trials (Keynote-024/189: 26.3/22.0 months), the survival benefit relative to chemotherapy was similar.
conclusionOur nationwide study demonstrated a survival benefit over conventional chemotherapy of a similar magnitude as observed in clinical trials and confirms the effectiveness of pembrolizumab in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.